Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

Phase 2mosliciguatNeutral

AI Analysis

Summary

Roivant announced Phase 2 PHocus study topline results for mosliciguat in PH-ILD patients will be presented at ERS Congress 2026 on September 8, 2026, with an accompanying investor call scheduled for the same day.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Topline results to be presented at ERS Congress 2026

Importance:6/10

Sentiment:

0.00

Phase 2 datapulmonary hypertensioninterstitial lung diseaseconference presentationinvestor call

Related Companies

$ROIV

Read the original article

Published by GlobeNewswire Clinical Studies on September 6, 2026 5:00 AM

Read Original